Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tumor Lymphocytic Infiltration in NSCLC

Assessing its prognostic value

Publish date:: February 9, 2016

Intense lymphocytic infiltration, found in a minority of tumors, was validated as a favorable prognostic marker for survival in resected non–small-cell lung cancer. This according to a study evaluating the benefit of platinum-based adjuvant chemotherapy in non-small-cell lung cancer (NSCLC), including a discovery set of 824 patients with NSCLC and a validation set of 984 patients with NSCLC. Researchers found:

Tumor lymphocytic infiltration (TLI) was intense in 11% of patients in the discovery set vs 6% in the validation set.

Prognostic value of TLI in the discovery set was: overall survival (HR=0.56), disease-free survival (HR=0.59), and specific disease-free survival (HR=0.56).

Prognostic value of TLI was confirmed in the validation set: OS (HR=0.45), DFS (HR=0.44), and SDFS (HR=0.42) with no heterogeneity across trials.

No significant predictive effect was seen for TLI.

Citation: Brambilla E, Le Teuff G, Marguet S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non–small-cell lung cancer. [Published online ahead of print February 1, 2016]. J Clin Oncol. doi:10.1200/JCO.2015.63.0970.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,